CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

← Biogen Inc. (BIIB) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫

Biogen Inc. (BIIB)

Biological Products, (No Diagnostic Substances) · market cap $33.1B · as of 2026-07-09

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst
2026-12-01 (est.)
Phase 3
Pipeline
20
programs
Upcoming events
8
next 90d+
Dossier
Ready
cached
Biogen Inc. (BIIB) is a Cambridge-based large-cap neuroscience biotechnology company with ~$9.9B in 2025 revenues, anchored by a maturing multiple sclerosis franchise (~45% of 2024 revenues), Spinraza in SMA (16.2%), and the recently approved Leqembi (Alzheimer's) and Tofersen (ALS-SOD1). The stock trades at ~$205.70 against a consensus analyst mean target of ~$220, with a net debt position of ~$2.9B and a broad late-stage pipeline spanning neurology, immunology, and rare disease. A Phase 3 readout for litifilimab in systemic lupus erythematosus is the highest-importance near-term catalyst, expected around September 2026.
The catalyst path
  • 2026-12-01 (est.)Phase 3 · Felzartamabimp 9/10
  • 2026-12-31 (est.)Phase 3 · Lecanemab SCimp 9/10
  • 2027-01-15 (est.)Phase 2 · Tofersenimp 7/10
  • 2027-03-15 (est.)Phase 3 · anti-TNF therapyimp 9/10
  • 2027-05-20 (est.)Phase 3 · BIIB017 (peginterferon beta-1a)imp 9/10
  • 2027-05-31 (est.)Phase 3 · Felzartamabimp 9/10
  • 2027-06-25 (est.)Phase 2 · APL-3007, pegcetacoplan (APL-2)imp 7/10
  • 2027-07-15 (est.)Phase 3 · Pegcetacoplanimp 9/10
Pipeline
AssetPhaseIndication
LeqembiApprovedAlzheimer Disease
BIIB080Phase 2Alzheimer Disease
TofersenApprovedALS (SOD1)
APL2Phase 3FSGS
APL-3007, pegcetacoplan (APL-2)Phase 2Geographic Atrophy Secondary to Age-related Macular Degeneration
Lecanemab SCPhase 3Early Alzheimer's Disease
Antiparkinsonian Agent(s)Phase 2Parkinson Disease
Lecanemab IVPhase 3Early Alzheimer's Disease
PegcetacoplanPhase 3C3G
Baminercept alfa 3Phase 2Rheumatoid Arthritis
Baminercept alfa 4Phase 2Rheumatoid Arthritis
Baminercept alfa 2Phase 2Rheumatoid Arthritis
Baminercept alfa 5Phase 2Rheumatoid Arthritis
CVPPhase 2Non-Hodgkins Lymphoma
DextromethorphanPhase 3Relapsing-Remitting Multiple Sclerosis
SAGE 217Phase 3Postpartum Depression
Ibritumomab TiuxetanPhase 2Non-Hodgkins Lymphoma
BIIB019 (Daclizumab)Phase 3Relapsing-Remitting Multiple Sclerosis
meningococcal polysaccharide diphtheria conjugate vaccine (quadrivalent)Phase 2Relapsing Forms of Multiple Sclerosis
S-warfarinPhase 3Relapsing-Remitting Multiple Sclerosis
Price & technical context
3-month
+19.6%
6-month
+32.4%
12-month
+54.3%
52-wk range
$164.42–$254.87
vs 50-day MA
+8.6%
vs 200-day MA
+23.7%
Realized vol
34.2%
Max drawdown
-37.4%

Daily closes through 2026-11-16. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

Sources & data
  • SEC filings — EDGAR filings for BIIB (10-K, 10-Q, S-3, 13D/G, Form 4)
  • Clinical trials — 20 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
  • Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
  • Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.